Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug

Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation 
of a Phase 1 Clinical Trial of Anticancer Drug MRX34 
Novel SMARTICLES(R) Technology Used to Deliver First-Ever microRNA
Oncology Compound in Clinical Development 
BOTHELL, WA -- (Marketwired) -- 05/13/13 --   Marina Biotech, Inc.
(PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and
development company, today announced that the Company's licensee,
Mirna Therapeutics, has reported that they have initiated a Phase 1
clinical study of MRX34, the first miRNA to advance into a human
clinical trial for cancer. The Phase 1 trial is being conducted in
patients with unresectable primary liver cancer or metastatic cancer
with liver involvement. 
"We are pleased to see the SMARTICLES delivery technology advance
into another clinical development effort," stated Richard Ho M.D.,
Ph.D., Executive Vice President, Research and Development at Marina
Biotech. "With the initiation of this trial, Marina will be the only
company with a delivery technology that is being used to deliver both
single-stranded and double-stranded oligonucleotide therapeutics in
clinical trials. We look forward to Mirna's continued advancement of
this program and the validation of our oligonucleotide delivery
platform." 
The Phase 1 MRX34 study will follow a standard oncology study design,
consisting of an initial dose-escalation phase followed by an
enrichment phase, and is expected to enroll up to 48 patients in
total. MRX34 is a miRNA "mimic" of tumor suppressor miR34 delivered
using SMARTICLES. Mirna filed its first Investigational New Drug
Application with the U.S. Food and Drug Administration for MRX34
earlier this year. Additional information on the study and enrollment
can be found at clinicaltrials.gov
(http://clinicaltrials.gov/ct2/show/NCT01829971). Mirna's program is
funded in part by a Cancer Prevention and Research Institute of Texas
(CPRIT) Commercialization grant. 
About Amphoteric Liposomes
 Amphoteric liposomes define a novel class
of liposomes, which are pH dependent charge-transitioning particles
that provide for the delivery of a nucleic acid payload (e.g., siRNA,
microRNA, antisense, decoy, etc.) to cells either by local or
systemic administration. Amphoteric liposomes are designed to release
their nucleic acid payload within the target cell where the nucleic
acid can then engage a number of biological pathways, including the
RNA interference pathway, and thereby exert a therapeutic effect.
Currently, Marina Biotech amphoteric liposomal delivery technology
includes non-DiLA2 based amphoteric liposomes (or SMARTICLES(R)) and
DiLA2 based amphoteric liposomes. 
About Marina Biotech, Inc.
 Marina Biotech is a biotechnology company
focused on the development and commercialization of
oligonucleotide-based therapeutics utilizing multiple mechanisms of
action including RNA interference (RNAi) and messenger RNA
translational blocking. The Marina Biotech pipeline currently
includes a clinical program in Familial Adenomatous Polyposis (a
precancerous syndrome) and two preclinical programs -- in bladder
cancer and myotonic dystrophy. Marina Biotech has entered into an
agreement with both Mirna Therapeutics and ProNAi Therapeutics to
license Marina Biotech's SMARTICLES(R) technology for the delivery of
microRNA mimics and DNAi, respectively. In addition, Marina Biotech
announced exclusive licensing agreements with Monsanto Company for
Marina Biotech's delivery and chemistry technologies and with
Girindus America for the supply of CRN-based oligonucleotides. Marina
Biotech recently entered into non-exclusive agreements with Novartis
Institutes for Biomedical Research and Tekmira Pharmaceuticals to
license Marina Biotech's CRN and UNA nucleic acid modification
chemistries, respectively. Marina Biotech's goal is to improve human
health through the development of RNAi- and oligonucleotide-based
compounds and drug delivery technologies that together provide
superior therapeutic options for patients. Additional information
about Marina Biotech is available at http://www.marinabio.com. 
Forward-Looking Statements 
Statements made in this news release may be forward-looking
statements within the meaning of Federal Securities laws that are
subject to certain risks and uncertainties and involve factors that
may cause actual results to differ materially from those projected or
suggested. Factors that could cause actual results to differ
materially from those in forward-looking statements include, but are
not limited to: (i) the ability of Marina Biotech to obtain
additional funding in the near term; (ii) the ability of Marina
Biotech to attract and/or maintain manufacturing, research,
development and commercialization partners; (iii) the ability of
Marina Biotech and/or a partner to successfully complete product
research and development, including preclinical and clinical studies
and commercialization; (iv) the ability of Marina Biotech and/or a
partner to obtain required governmental approvals; and (v) the
ability of Marina Biotech and/or a partner to develop and
commercialize products prior to, and that can compete favorably with
those of, competitors. Additional factors that could cause actual
results to differ materially from those projected or suggested in any
forward-looking statements are contained in Marina Biotech's most
recent periodic reports on Form 10-K and Form 10-Q that are filed
with the Securities and Exchange Commission. Marina Biotech assumes
no obligation to update and supplement forward-looking statements
because of subsequent events. 
Contact:
Michael French
Chief Executive Officer
(425) 892-4322
admin@marinabio.com 
 
 
Press spacebar to pause and continue. Press esc to stop.